FMP
Aeglea BioTherapeutics, Inc.
AGLE
NASDAQ
Inactive Equity
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
12.01 USD
0.75 (6.24%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. Jonathan D. Alspaugh M.B.A.
sector
Healthcare
industry
Biotechnology
website
https://www.aeglea.comexchange
NASDAQ
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly kno...
CIK
0001636282
ISIN
US00773J2024
CUSIP
00773J103
Address
805 Las Cimas Parkway
Phone
512 942 2935
Country
US
Employee
69
IPO Date
Apr 7, 2016
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
AGLE Financial Summary
CIK
0001636282
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
00773J103
ISIN
US00773J2024
Country
US
Price
12.01
Beta
2.57
Volume Avg.
59.54k
Market Cap
48.63M
Shares
-
52-Week
2.66-24.0
DCF
8.39
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.16
P/B
-
Website
https://www.aeglea.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest AGLE News
It looks like there's no news available.
